Generic Name: Disodium pamidronate
Product Name: Aredia
Aredia is used in the treatment of:
- Paget’s disease of bone.
- Hypercalcaemia of malignancy.
- Osteolytic bone metastases from breast cancer and multiple myeloma.
Disodium pamidronate inhibits osteoclasts, specific cells responsible for destruction of bone. Osteoclast precursors enter the bone from the bloodstream, and they eventually mature to become osteoclasts. In certain conditions, mature osteoclasts are responsible for destruction of bone and release of calcium into the bloodstream. Pamisol suppresses the migration of osteoclast precursors into bone, thereby preventing bone destruction and increased calcium levels.
- The initial recommended dose is 60 mg given by intravenous infusion at a rate of 15 mg/hour.
- The dosing regimen is then adjusted according to the individual patient response.
Hypercalcaemia of malignancy:
- Pamidronate is given by intravenous infusion at a rate of 60 mg/hour.
- The dose is adjusted according to the initial plasma concentration of calcium.
- For concentrations less than 3.0 mmol/L, 30 mg is given.
- 3.0 to 3.5 mmol/L 30-60 mg is given.
- 3.5 to 4.0 mmol/L 60-90 mg is given.
- Greater than 4.0 mmol/L 90 mg is given.
- The dose is repeated every 2 to 3 weeks as required.
- The recommended dose is 90 mg by intravenous infusion over 2 hours in breast cancer patients, and over 4 hours in patients with multiple myeloma.
- This dose is repeated every 3 to 4 weeks.Pamidronate should be avoided during pregnancy and lactation.
Common side effects
Common side effects of this medication include:
Uncommon side effects
Some of the rarer side effects of this medication include:
- Inflammation and ulceration of the oesophagus
- Inflammation of the tongue
- Eye irritation
- Heart failure
- Kidney function impairment
- AMH Pty Ltd. Pamidronate. Australian Medicines Handbook: July, 2005.
- MIMS Australia Pty Ltd. Aredia. MIMS Online 2003. Available from: [URL Link]
For further information talk to your doctor.